IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity

COVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity or as a therapeutic has yet been developed to SARS-CoV-2. In this study we discover and chara...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:bioRxiv
Autores principales: Ejemel, Monir, Li, Qi, Hou, Shurong, Schiller, Zachary A., Wallace, Aaron L., Amcheslavsky, Alla, Yilmaz, Nese Kurt, Toomey, Jacqueline R., Schneider, Ryan, Close, Brianna J., Chen, Da-Yuan, Conway, Hasahn L., Mohsan, Saeed, Cavacini, Lisa A., Klempner, Mark S., Schiffer, Celia A., Wang, Yang
Formato: Artigo
Lenguaje:Inglês
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7263543/
https://ncbi.nlm.nih.gov/pubmed/32511396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2020.05.15.096719
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares